Fixed-Dose Combination Drugs refer to the combination of different drugs in a capsule or a tablet. There are mainly two types of fixed-dose combination drugs- rational fixed-dose combination drugs and irrational fixed-dose combination drugs. The rationality of fixed-dose combination drugs should be based on the mechanism of different drugs, in a particular drug combination, pharmacokinetics and the toxicity of the different ingredients in the fixed-dose combination drug. Fixed-dose combination drugs are very popular in the Indian pharmaceutical market. Most of the fixed-dose combination drugs, introduced in the Indian pharmaceutical market are irrational drugs. Hence, many drugs have been banned in India because of the occurrence of adverse reactions of different ingredients in the drug.
Also, there are many advantages of fixed-dose combination drugs, especially for patients in lower income or middle income developing countries. The increasing prevalence of diabetes, allows the diabetic population to have these fixed-dose combination drugs as their standard treatment as they are cost-effective and also their distribution is potentially huge. Fixed-dose combination drugs are very convenient for some of the patients, especially those, who are not comfortable in taking many numbers of tablets.
Fixed-dose combination drugs are used in the treatment of various chronic diseases and are easily available at different drug stores and pharmacies.
The increasing prevalence of tuberculosis is one of the major factor driving the growth of the fixed-dose combination drugs market. High intake of junk food and the adoption of poor lifestyle habits such as lack of physical activities, lead to a high prevalence of cardiovascular diseases, which is expected to drive the fixed-dose combination drugs market. Increasing healthcare awareness is another important factor, which can increase the demand of fixed-dose combination drugs. Other factors such as more number of diagnostic laboratories and hospitals, increasing obesity, high disposable income, and increased risk factors, leading to more number of chronic disorders, are expected to increase the growth of fixed-dose combination drugs market.
There are many issues and challenges associated with fixed-dose combination drugs such as chemical non-compatibility which leads to decreased shelf life, drugs interactions because of having a common metabolic pathway, having different efficacy at different times. These challenges are expected to hinder the growth of fixed-dose combination drugs market. Fixed-dose combination drugs can only be permitted by state licensing authority. The fixed-dose combination drugs are banned in many countries because of the presence of side effects such as harmful reactions caused by these drugs, which ultimately allows the patients to reduce the use of fixed-dose combination drugs.
The global Fixed-Dose Combination Drugs market is segmented on the basis of product type, indication, distribution channel, and geography:
Based on the product type, the Fixed-Dose Combination Drugs are segmented into rational fixed-dose combination rugs and irrational fixed-dose combination drugs. Rational fixed-dose combination drugs are the drugs that have an accurate ratio of each drug. Irrational fixed-dose combinational drugs do not have an accurate ratio of all the drugs and can be very harmful. Hence, rational fixed-dose combination drugs are expected to hold the maximum revenue share in the overall fixed-dose combination drugs market. Many fixed-dose combination drugs, introduced in India are irrational. The Indian drug control Authority has banned many fixed-dose combination drugs because of the adverse reaction caused by these drugs. The fixed-dose combination drugs are used in the treatment of many chronic disorders such as tuberculosis, cardiovascular diseases, treatment of renal failure and many other chronic diseases.
Geographically, the global fixed-dose Combination drugs market is segmented into a few key regions viz. North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East & Africa. North America is expected to dominate the global market due to advancements in the field of healthcare and high obese population. Europe is expected to hold the second largest share in the global Fixed-Dose Combination Drugs market because of the presence of a large population. The Asia Pacific is expected to hold a large share in the fixed-dose Combination drugs market due to increasing healthcare awareness among the population and a large number of hospitals and diagnostic laboratories.
Some of the players identified in the global Fixed-Dose Combination Drugs market are Halo Pharma,
The report covers exhaustive analysis on:
Regional analysis includes